US House advances $95 billion Ukraine-Israel package toward Saturday vote

The legislation transfers frozen Russian assets to Ukraine, impose sanctions on Hamas, Iran, and ByteDance.


REUTERS April 20, 2024

WASHINGTON:

The US House of Representatives advanced a $95 billion legislative package on Friday providing aid to Ukraine, Israel, and the Indo-Pacific in a broad bipartisan vote, overcoming hardline Republican opposition that had held it up for months.

Friday's procedural vote, which passed 316-94 with more support from Democrats than the Republicans who hold a narrow majority, advanced a package similar to a measure that passed the Democratic-majority Senate in February.

Democratic President Joe Biden, Democratic Senate Majority Leader Chuck Schumer, top Senate Republican Mitch McConnell, and top House Democrat Hakeem Jeffries had been pushing for a House vote since then Republican House Speaker Mike Johnson had held off in the face of opposition from a small but vocal segment of his party.

In addition to the aid for allies, the package includes a provision to transfer frozen Russian assets to Ukraine, sanctions targeting Hamas and Iran, and force China's ByteDance to sell social media platform TikTok face a ban in the US.

The legislation provides more than $95 billion in security assistance, including $9.1 billion for humanitarian aid, which Democrats had demanded.

If the House passes the measure, as expected, the Senate will need to follow suit to send it to Biden to sign into law.

Schumer on Friday told senators to be prepared to come back over the weekend if needed.

Some conservative lawmakers oppose aid to Ukraine, and Republican presidential candidate Donald Trump has sent mixed messages about it.

Some Democrats also oppose certain provisions in the bill, notably on Israel aid, and have pushed for more conditions on that assistance.

 

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ